Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare types of systemic amyloidosis. 124I-evuzamitide PET/CT demonstrated uptake in multiple organs with amyloid deposition utilizing cutoffs from automated quantification in patients […]
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
WAKIX® (pitolisant) Net Revenue of $201.3 Million for Fourth Quarter and $714.7 Million for Full Year 2024; Representing Growth of 23% in Year-Five on the Market 2025 WAKIX Net Revenue Guidance Between $820 – $860 Million; On Track Toward a Potential $1 Billion+ Opportunity Committed to Leadership in Sleep/Wake with Next Generation Pitolisant Formulations and Orexin 2 Receptor Agonist; […]
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient […]
Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company’s proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential FREMONT, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — Attovia […]
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody […]
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune diseases, and EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical-stage biopharmaceutical company specializing in the discovery and development of multi-specific antibodies for diseases with high unmet need, announced that the companies […]
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
Preclinical data presented at Cell Symposia conference show a small molecule directed at a pathogenic RNA achieved reversal of myotonia in an animal model of myotonic dystrophy Type 1 (DM1)
Supports additional product development with Company’s multi-modality rSM drug platform, broadening the reach of genetic medicine and offering the potential to treat diseases at their root cause with oral medicines
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
Financing led by Frazier Life Sciences with participation from new investors including Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors and Columbia Threadneedle MONTREAL, Nov. 26, 2024 (GLOBE NEWSWIRE) — 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced the closing of an oversubscribed $53 million Series C financing. The company […]
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical stage biotechnology company positioned to lead the development of T-cell engagers for autoimmune diseases, appointed repeatedly successful industry veterans, Angie You, Ph.D. and Dan Puckett, to its board of directors. “T-cell engagers have the potential to tranform the treatment of many autoimmune diseases. Ken has assembled a […]
